Protection of mice from lethal influenza virus infection with high dose-short duration ribavirin aerosol.

AUTOR(ES)

Wyde, P R

RESUMO

An aerosol generated from a reservoir containing 60 mg of ribavirin per ml given for 2 h twice daily for 4 days afforded the same high level of protection against lethal influenza virus infection of mice as a longer, conventional treatment schedule (20 mg/ml given for 11 h daily for 4 days). Incremental decreases in ribavirin concentration made while maintaining the 2-h intermittent schedule provided progressively less protection of mice. Mice exposed to the 60-mg/ml doses had significantly increased pulmonary and serum drug levels when compared with mice given 20 mg of drug per ml, these increases were transient, and no evidence of pulmonary intolerance was detected. These studies suggest that protective effects of ribavirin against influenza virus infection can be achieved without untoward effects if higher doses and shorter periods of administration are used.

Documentos Relacionados

• Treatment of influenza A (H1N1) virus infection with ribavirin aerosol.
• Aerosol and intraperitoneal administration of ribavirin and ribavirin triacetate: pharmacokinetics and protection of mice against intracerebral infection with influenza A/WSN virus.
• Ribavirin small-particle-aerosol treatment of influenza B virus infection.
• Lack of Interference of Guanosine with Ribavirin Aerosol Treatment of Influenza A Infection in Mice
• Amantadine and ribavirin aerosol treatment of influenza A and B infection in mice.